Medroxyprogesterone vs Tadalafil: side-by-side comparison
Medroxyprogesterone (Progestin) and Tadalafil (PDE5 inhibitor) belong to different therapeutic classes and are rarely substitutes for each other. The comparison is useful when a single patient is weighing both options for adjacent or overlapping needs.
| Property | Medroxyprogesterone | Tadalafil |
|---|---|---|
| Therapeutic class | Progestin | PDE5 inhibitor |
| CAS | 520-85-4 | 171596-29-5 |
| ATC | G03DA02 | G04BE08 |
| Molecular weight | 344.49 g/mol | 389.4 g/mol |
| Brands with this active ingredient | 1 | 7 |
What they share
Medroxyprogesterone and Tadalafil share the common regulatory framework for prescription active ingredients, bioequivalence standards for generics, and pharmacist oversight. Beyond that, points in common are limited.
Key differences
Medroxyprogesterone acts by a different mechanism than Tadalafil, with indications that barely overlap. Comparing the two is useful when a clinician has mentioned both in the same context or the patient wants to understand why one was prescribed instead of the other.
Mechanisms compared
Medroxyprogesterone: La médroxyprogestérone se lie aux récepteurs de la progestérone et exerce de puissants effets progestatifs : épaississement de la glaire cervicale, inhibition de l'ovulation, amincissement de l'endomètre et réduction des… Tadalafil: Le tadalafil inhibe sélectivement la PDE5, l'enzyme chargée de dégrader le guanosine monophosphate cyclique dans le corps caverneux et dans d'autres muscles lisses vasculaires.
Indications compared
Medroxyprogesterone: La médroxyprogestérone est autorisée dans l'aménorrhée, les saignements utérins anormaux d'origine hormonale, la prévention de l'hyperplasie endométriale chez la femme ménopausée recevant un estrogène, et la prévention d… Tadalafil: Le tadalafil dispose de trois indications autorisées : la dysfonction érectile chez l'homme adulte, les troubles urinaires du bas appareil liés à l'hypertrophie bénigne de la prostate, et l'hypertension artérielle pulmon…
Safety profile
Medroxyprogesterone: Les effets indésirables fréquents de la forme orale comprennent saignements irréguliers, tension mammaire, variations de l'humeur, rétention hydrique et prise de poids. Tadalafil: Les effets indésirables fréquents observés dans les essais cliniques comprennent céphalées, dyspepsie, douleurs dorsales, myalgies, congestion nasale et bouffées vasomotrices du visage.
Questions fréquentes
Is Medroxyprogesterone better than Tadalafil? ▾
Medroxyprogesterone and Tadalafil are not "better or worse" — they treat different things. The sensible question is which fits your specific need.
Can Medroxyprogesterone and Tadalafil be combined? ▾
Whether they can be combined depends on the indications and the interaction profile of each. If both are in a single prescription, the prescriber has weighed it; in self-medication they should never be combined.
Do they have the same side-effect profile? ▾
No — they belong to different classes and have distinct side-effect profiles. Each has its own prescribing information.
Products with Medroxyprogesterone
Products with Tadalafil
Les informations publiées sur ce site sont fournies à titre documentaire et pédagogique. Elles ne remplacent pas l'avis d'un professionnel de santé qualifié.